(PRWEB) September 23, 2014
Proove Biosciences, the commercial and research leader in personalized medicine, will be presenting research on the association between specific genes and patients’ predisposition to anxiety disorders at the U.S. Psychiatric and Mental Health Congress’ 27th Annual Scientific Program in Orlando, Florida.
The 2014 conference focuses on the theme of ‘Embracing Change.’ Mental health, and healthcare as a whole, is currently experiencing a changing landscape. From the challenges presented by the Affordable Care Act to the growing need for effective integrative care strategies, the Psych Congress is being tasked with providing the most relevant, impactful program to date.
Proove conducted research on the association between certain human genes and anxiety. The Study consisted of 420 subjects from 10 clinical research sites throughout the U.S. Half the subjects had varying degrees of anxiety, while the other half acted as controls. Proove determined that the COMT gene showed association with anxiety disorders, and that females specifically had a prevalence of anxiety disorders. Proove’s study suggests that mutation in COMT may play a role in genetic predisposition to anxiety disorders.
“Anxiety is one of the most common mental health disorders that Americans suffer from, and Proove has conducted cutting-edge research on the links between an individual’s genes and their likelihood to suffer from the condition,” stated Brian Meshkin, CEO of Proove Biosciences. “ The U.S. Psych Congress Scientific Program focuses on expanding knowledge and tools that mental health professionals will be able to utilize when treating patients. Proove Biosciences’ research into the links between genetics and mental health disorders will help healthcare professionals better understand treatment options, and assess patients individually, rather than in a cookie-cutter framework.”
About Proove Biosciences
Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe genetic testing can provide such knowledge: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.
Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).